2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• 英文别名: 2,4-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• 化学式: C₁₃H₂₀BNO₂
• 分子量: 233.118
• InChiKey: APXPNTIPURIKQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.0
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromo-7-chloro-1-methyl-1,6-naphthyridin-2(1H)-one 、 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以290 mg的产率得到7-chloro-3-(4,6-dimethylpyridin-3-yl)-1-methyl-1,6-naphthyridin-2(1H)-one
  参考文献：
  名称：

  [EN] NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES
  [FR] COMPOSÉS NAPHTYRIDONE POUR L'INHIBITION DE KINASES RAF ET/OU DE TYROSINE KINASES BCR-ABL

  摘要：

  本公开涉及抑制RAF丝氨酸/苏氨酸蛋白激酶和Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如黑色素瘤、非小细胞肺癌和慢性髓细胞白血病（CML）中的用途。

  公开号：

  WO2022236319A1
• 作为产物：
  描述：

  2,4-二甲基-5-溴吡啶 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2,4-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
  参考文献：
  名称：

  [EN] NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES
  [FR] COMPOSÉS NAPHTYRIDONE POUR L'INHIBITION DE KINASES RAF ET/OU DE TYROSINE KINASES BCR-ABL

  摘要：

  本公开涉及抑制RAF丝氨酸/苏氨酸蛋白激酶和Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如黑色素瘤、非小细胞肺癌和慢性髓细胞白血病（CML）中的用途。

  公开号：

  WO2022236319A1

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• Iridium-catalyzed C–H borylation of pyridines
  作者：Scott A. Sadler、Hazmi Tajuddin、Ibraheem A. I. Mkhalid、Andrei S. Batsanov、David Albesa-Jove、Man Sing Cheung、Aoife C. Maxwell、Lena Shukla、Bryan Roberts、David C. Blakemore、Zhenyang Lin、Todd B. Marder、Patrick G. Steel

  DOI：10.1039/c4ob01565g

  日期：——

  The iridium-catalysed C–H borylation is a valuable and attractive method for the preparation of aryl and heteroaryl boronates. However, application of this methodology for the preparation of pyridyl and related azinyl boronates can be challenged by low reactivity and propensity for rapid protodeborylation, particularly for a boronate ester ortho to the azinyl nitrogen. Competition experiments have revealed that the low reactivity is due to inhibition of the active catalyst through coordination of the azinyl nitrogen lone pair at the vacant site on the iridium. This effect can be overcome through the incorporation of a substituent at C-2. Moreover, when this is sufficiently electron-withdrawing protodeborylation is sufficiently slowed to permit isolation and purification of the C-6 boronate ester. Following functionalization, reduction of the directing C-2 substituent provides the product arising from formal ortho borylation of an unhindered pyridine ring.

  铱催化的C-H硼化是一种有价值且有吸引力的方法，用于制备芳基和杂芳基硼酸酯。然而，这种方法在制备吡啶基及相关氮杂基硼酸酯时可能面临反应活性低和快速质子脱硼化的挑战，尤其是当硼酸酯位于氮杂基氮原子的邻位时。竞争实验揭示，低反应活性是由于氮杂基氮原子的孤对电子在铱的空位上配位，抑制了活性催化剂。通过在C-2位引入取代基可以克服这一效应。此外，当该取代基足够吸电子时，质子脱硼化过程会被足够减缓，从而允许分离和纯化C-6硼酸酯。经过功能化后，导向C-2取代基的还原提供了源自未受阻吡啶环形式邻位硼化的产物。
• [EN] PYRIDINYL BASED APOPTOSIS SIGNAL-REGULATION KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE DE RÉGULATION DU SIGNAL APOPTOTIQUE À BASE DE PYRIDINYLE
  申请人：FRONTHERA U S PHARMACEUTICALS LLC

  公开号：WO2018151830A1

  公开（公告）日：2018-08-23

  Apoptosis signal-regulating kinase 1 (ASK1) activation and signaling have been reported to play an important role in a broad range of diseases including neurodegenerative, cardiovascular, inflammatory, autoimmunity and metabolic disorders. Disclosed herein is the synthesis of pyridinyl derived therapeutic agents that function as inhibitors of ASK 1 as well as their pharmaceutical compositions and methods of use.

  细胞凋亡信号调节激酶1（ASK1）的激活和信号传导据报道在包括神经退行性、心血管、炎症、自身免疫和代谢紊乱等广泛疾病中发挥重要作用。本文披露了一种以吡啶基衍生的治疗剂的合成，其作为ASK1的抑制剂以及它们的药物组合物和使用方法。
• [EN] NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES<br/>[FR] COMPOSÉS NAPHTYRIDONE POUR L'INHIBITION DE KINASES RAF ET/OU DE TYROSINE KINASES BCR-ABL
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022236319A1

  公开（公告）日：2022-11-10

  The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases and inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).

  本公开涉及抑制RAF丝氨酸/苏氨酸蛋白激酶和Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如黑色素瘤、非小细胞肺癌和慢性髓细胞白血病（CML）中的用途。